World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
120
Citations
71359
World Ranking
3680
National Ranking
201

Overview

Hartmut Goldschmidt is affiliated with the University Hospital Heidelberg in Germany. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Within these domains, their work focuses particularly on subfields including Hematology, Oncology, Molecular Biology, Genetics, and Immunology.

The scientist has contributed extensively to topics such as Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis, Cancer Treatment and Pharmacology, CAR-T Cell Therapy Research, Monoclonal and Polyclonal Antibodies Research, and Chronic Lymphocytic Leukemia Research.

Frequent publication venues for Hartmut Goldschmidt include Blood, Clinical Lymphoma Myeloma & Leukemia, Journal of Clinical Oncology, Leukemia, and Blood Cancer Journal.

Some of their recent significant papers include:

  • "Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma" (2021, New England Journal of Medicine)
  • "Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†" (2021, Annals of Oncology)
  • "Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project" (2022, Journal of Clinical Oncology)
  • "Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial" (2021, The Lancet Oncology)
  • "Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial" (2021, The Lancet Oncology)

Their collaborative network includes frequent coauthors such as Katja Weisel, Marc S. Raab, Niels Weinhold, Philippe Moreau, and Carsten Müller-Tidow.

Best Publications

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

    S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade

  • Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

    Paul G. Richardson;Pieter Sonneveld;Michael W. Schuster;David Irwin

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie

  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst

  • Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C Munshi;Larry D Anderson;Nina Shah;Deepu Madduri

  • Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Meletios A. Dimopoulos;Albert Oriol;Hareth Nahi;Jesus San-Miguel

  • Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

    Jesús Fernando San Miguel;Jesús Fernando San Miguel;Katja Weisel;Philippe Moreau;Martha Lacy

  • Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

    Meletios Athanasios Dimopoulos;Philippe Moreau;Antonio Palumbo;Douglas Edgar Joshua

  • Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

    Pieter Sonneveld;Ingo G.H. Schmidt-Wolf;Bronno Van Der Holt;Laila El Jarari

  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

    S. K. Kumar;J. H. Lee;J. J. Lahuerta;G. Morgan

  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

    Pieter Sonneveld;Hervé Avet-Loiseau;Sagar Lonial;Saad Usmani

  • Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

    Thierry Facon;Shaji Kumar;Torben Plesner;Robert Z Orlowski

  • Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    P. Moreau;J. San Miguel;P. Sonneveld;M. V. Mateos

  • Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma.

    Rainer Haas;Robert Möhle;Stefan Frühauf;Hartmut Goldschmidt

  • IMWG consensus on risk stratification in multiple myeloma

    W J Chng;A Dispenzieri;C-S Chim;R Fonseca

  • Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

    Paul Gerard Richardson;Pieter Sonneveld;Michael Schuster;David Irwin

  • Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

    M A Dimopoulos;P Moreau;E Terpos;M V Mateos

  • Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3

    Meletios Dimopoulos;Robert Kyle;Jean Paul Fermand;S. Vincent Rajkumar

  • Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

    Michele Cavo;Evangelos Terpos;Cristina Nanni;Philippe Moreau

  • Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

    Kai Neben;Henk M. Lokhorst;Anna Jauch;Uta Bertsch

Frequent Co-Authors

Anthony D. Ho
Anthony D. Ho University Hospital Heidelberg
Walter Zidek
Walter Zidek Charité - University Medicine Berlin
Anna Jauch
Anna Jauch Heidelberg University
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Axel Benner
Axel Benner German Cancer Research Center
Kari Hemminki
Kari Hemminki Charles University
Thierry Rème
Thierry Rème Grenoble Alpes University
Gareth J. Morgan
Gareth J. Morgan Boston University
Michele Cavo
Michele Cavo University of Bologna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine doesn’t only mean becoming a doctor. There are many alternative online degree options in healthcare that offer flexibility and strong career prospects. For example, registered nurses looking to advance quickly can consider the easiest online dnp programs, which allow for doctoral-level training with a more accessible approach.

Those aiming to jump into patient care at an entry-level can benefit from the fastest lpn program options available online, helping you start work sooner. Mental health is another rapidly growing field, and the shortest online pmhnp programs offer fast-track routes to become a psychiatric nurse practitioner.

If you’re interested in the business and leadership side of healthcare, healthcare administration degrees focus on management, policy, and operations. These pathways offer diverse career options and can often be completed fully online, making them accessible for working professionals or career changers.

Best Scientists Citing Hartmut Goldschmidt

Trending Scientists